Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0429 • ACR Convergence 2022
No Change in Serum Levels of Bone Turnover Markers Corrected for Age and Gender During the First Year of Secukinumab Treatment in Patients with Ankylosing Spondylitis
Mark Siderius¹, Suzanne Arends², Freke Wink³ and Anneke Spoorenberg², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In patients with ankylosing spondylitis (AS), TNF-α inhibitors influence the course of serum bone turnover markers (BTM), favoring an increase in mineralization during the…
Abstract Number: 1045 • ACR Convergence 2022
Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images
Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our research group has shown that computer analysis of static images can be used…
Abstract Number: 1497 • ACR Convergence 2022
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Karolina Benesova¹, Oliver Hansen², Uta Kiltz³, Jan Brandt-Juergens⁴, Peter Kästner⁵, Elke Riechers⁶, Daniel Peterlik⁷, Christina Budden⁷, Annika Boas⁷, Stefanie Welle⁷ and Hans-Peter Tony⁸, ¹University Hospital Heidelberg, Heidelberg, Germany, ²Medizinische Abteilung V - Rheumatologie, Universitätsklinikum, Heidelberg, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁶Medizinische Hochschule Hannover, Hannover, Germany, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: In both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for…
Abstract Number: 0292 • ACR Convergence 2022
Malignancy in the Upadacitinib Clinical Trial Programs for Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Andrea Rubbert-Roth¹, Adriana Kakehasi², Tsutomu Takeuchi³, Marc Schmalzing⁴, Hannah Palac⁵, Jianzhong Liu⁵, Samuel Anyanwu⁵, Ralph Lippe⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ²Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ³Keio University and Saitama Medical University, Tokyo, Japan, ⁴University Hospital Wuerzburg, Wuerzburg, Germany, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc, Wiesbaden, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased risk of malignancies has been associated with chronic inflammation, as well as immunosuppressive and immunomodulatory therapies. The objective of this analysis is to…
Abstract Number: 0406 • ACR Convergence 2022
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
Sinead Maguire¹, Fiona Wilson², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Trinity College Dublin, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of…
Abstract Number: 0430 • ACR Convergence 2022
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Mark Siderius¹, Anneke Spoorenberg², Freke Wink³ and Suzanne Arends², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…
Abstract Number: 1112 • ACR Convergence 2022
Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry
Hafsah Nabi¹, Oliver Hendricks², Dorte Vendelbo Jensen³, Anne Gitte Loft⁴, Jens Pedersen⁵, Søren Just⁶, Kamilla Danebod⁷, Heidi Munk⁸, Salome Kristensen⁹, Natalia Manilo¹⁰, Ada Colic¹¹, Asta Linauskas¹², Pia Høger Thygesen¹³, Louise Christensen³, Maren Høgberget Kalisz³, Niels Lomborg¹⁴, Stavros Chrysidis¹⁵, Johnny Raun¹⁵, Marlene Andersen¹⁶, Frank Mehnert¹⁷, Niels Steen Krogh¹⁸, Merete L Hetland¹⁹ and Bente Glintborg²⁰, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, ²Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ³Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, ⁴Aarhus University, Horsens, Denmark, ⁵Svendborg Hospital, Odense University Hospital, Odense, Denmark, ⁶Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ⁷Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, ⁹Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹¹Department of Rheumatology, Zealand University Hospital, Køge, Denmark, ¹²North Denmark Regional Hospital, Hjørring, Denmark, ¹³Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁴Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Denmark, Odense, Denmark, ¹⁵Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, ¹⁶Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ¹⁷Aarhus University Hospital, Aarhus, Denmark, ¹⁸ZiteLab ApS, Frederiksberg, Denmark, ¹⁹Rigshospitalet, Glostrup, Denmark, ²⁰Rigshospitalet, Glostrup, Virum, Denmark
Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…
Abstract Number: 1509 • ACR Convergence 2022
Patient Clusters Identified by Machine Learning from a Pooled Analysis of the Clinical Development Program of Secukinumab in Psoriatic Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis with Axial Manifestations
Xenofon Baraliakos¹, Effie Pournara², Dafna Gladman³, Philip J Mease⁴, Samad S Jahandideh² and Laura Coates⁵, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Universally acceptable clinical and imaging criteria to define axial psoriatic arthritis (PsA) is lacking.1 Machine learning (ML) algorithms can detect patterns from large clinical…
Abstract Number: 0372 • ACR Convergence 2022
Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry
Kyung Min Ko¹ and Su-Jin Moon², ¹International St. Mary's Hospital, Incheon, Republic of Korea, ²Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Infection is a perpetual concern in patients treated with biological therapy. However, long-term real-world data on infectious profile of AS patients are lacking The…
Abstract Number: 0409 • ACR Convergence 2022
Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Philip J Mease¹, Atul Deodhar², Maxime Dougados³, Maureen Dubreuil⁴, Marina Magrey⁵, Helena Marzo-Ortega⁶, Martin Rudwaleit⁷, Christine de la Loge⁸, Alicia Ellis⁹, Carmen Fleurinck¹⁰, Marga Oortgiesen¹¹, Vanessa Taieb¹² and Lianne Gensler¹³, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁴Department of Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Case Western Reserve University, University Hospitals, Richfield, OH, ⁶Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁸UCB Pharma, Brussels, Belgium, ⁹UCB Pharma, Raleigh, ¹⁰UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²UCB Pharma, Colombes, France, ¹³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ improved signs and symptoms and reduced disease activity…
Abstract Number: 0431 • ACR Convergence 2022
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept
Ana Lúcia Martins Fernandes¹, Ana Pinto², Kalveer flora³, dilpreet matharu³, anthony isaacs³ and Pedro Machado⁴, ¹Centro Hospitalar Universitário do Algarve, Faro, Portugal, ²Local Health Unit of Guarda, Barcelos, Portugal, ³Northwick Park Hospital, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Biotherapeutics have revolutionized the treatment of axial spondyloarthritis (axSpA). The emergence of biosimilars allowed substantial savings and a wider access to treatment, and international…
Abstract Number: 1151 • ACR Convergence 2022
Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology
Alec Furst¹, John Davis¹, Manuel Rodriguez¹, Kimberly Ogle¹, James T. Rosenbaum² and Tejpal Gill¹, ¹OHSU, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is defined clinically as inflammatory back pain along with peripheral arthritis, and extra-articular manifestations involving the eye, gut, and skin. Even…
Abstract Number: 1514 • ACR Convergence 2022
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral for suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis in patients with chronic back pain (CBP).…
Abstract Number: 0374 • ACR Convergence 2022
The BASDAI Index During Pregnancy
Olga Krichevskaya, Tatiana Dubinina, Ekaterina Ilinih, Svetlana Glukhova, Anastasia Demina and Irina Andrianova, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: During pregnancy, BASDAI may reflect not only the activity of ankylosing spondylitis (AS), but also back pain and fatigue, that are associated with the…
Abstract Number: 0410 • ACR Convergence 2022
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Marina Magrey¹, Atul Deodhar², Philip J Mease³, Victoria Navarro-Compán⁴, Sofia Ramiro⁵, Martin Rudwaleit⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Vanessa Taieb⁹, Michael Frank Mørup¹⁰, Marga Oortgiesen¹¹ and Jonathan Kay¹², ¹Case Western Reserve University, University Hospitals, Richfield, OH, ²Oregon Health & Science University, Portland, OR, USA, Portland, OR, ³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, ⁹UCB Pharma, Colombes, France, ¹⁰UCB Pharma, Copenhagen, Denmark, ¹¹UCB Pharma, Raleigh, NC, ¹²Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: Examine the association between achieving increasingly stringent clinical response criteria and lower levels of disease activity, and improvements in physical function and health-related quality…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].